This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Effect of Moisturizing Creams on Skin Barrier Function

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified October 2008 by ACO Hud Nordic AB.
Recruitment status was:  Recruiting
Information provided by:
ACO Hud Nordic AB Identifier:
First received: October 10, 2008
Last updated: NA
Last verified: October 2008
History: No changes posted
This study is a randomized, double-blind, placebo-controlled bilateral study on the effect of moisturizing creams on skin barrier function. The hypothesis is that a new active emulsion has a better influence on skin barrier function comapred to its placebo.

Condition Intervention Phase
Atopic Eczema Drug: urea/lactic acid Drug: Placebo Phase 4

Study Type: Interventional

Resource links provided by NLM:

Further study details as provided by ACO Hud Nordic AB:

Arms Assigned Interventions
Active Comparator: new emulsion Drug: urea/lactic acid
new emulsion type
Placebo Comparator: new emulsion placebo Drug: Placebo
only emulsion base


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Dry skin barrier disorders such as atopic dermatitis or Malassezia eradicated head and neck dermatitis.
  • Rough or clinically normal skin on the volar aspect of the forearm.
  • Either gender
  • Age between 18 and 65 years
  • Written Informed Consent

Exclusion Criteria:

  • Possible allergy to ingredients in the study medications.
  • Use of any concomitant medication that may interfere with the study related activities or assessment of efficacy.
  • Any patient related factor suggesting potential poor compliance with study procedures (e.g. psychiatric disorders, history of alcohol or substance abuse).
  • Any serious medical condition which, in the opinion of the investigator, may interfere with the evaluation of the results.
  • Pregnancy or breast feeding, or patients who plan to become pregnant during the course of the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00771121

Contact: Lena Holm, Dr +46 (0)706-382722

Sophiahemmet Recruiting
Stockholm, Sweden, 114 86
Contact: Lena Holm, Dr    +46 (0)706-382722   
Sophiahemmet Recruiting
Stockholm, Sweden, 114 86
Contact: Lena Holm, Dr    0706-382722   
Principal Investigator: Lena Holm, Dr         
Sponsors and Collaborators
ACO Hud Nordic AB
  More Information Identifier: NCT00771121     History of Changes
Other Study ID Numbers: ACO2008-CT-01
Study First Received: October 10, 2008
Last Updated: October 10, 2008

Additional relevant MeSH terms:
Dermatitis, Atopic
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases
Skin Diseases, Eczematous
Hypersensitivity, Immediate
Immune System Diseases processed this record on September 21, 2017